228 related articles for article (PubMed ID: 10698671)
1. Preclinical evaluation of the cardiotoxicity of taxane-anthracycline combinations using the model of isolated perfused rat heart.
Platel D; Pouna P; Bonoron-Adèle S; Robert J
Toxicol Appl Pharmacol; 2000 Mar; 163(2):135-40. PubMed ID: 10698671
[TBL] [Abstract][Full Text] [Related]
2. Defective taxane stimulation of epirubicinol formation in the human heart: insight into the cardiac tolerability of epirubicin-taxane chemotherapies.
Salvatorelli E; Menna P; Gianni L; Minotti G
J Pharmacol Exp Ther; 2007 Feb; 320(2):790-800. PubMed ID: 17135345
[TBL] [Abstract][Full Text] [Related]
3. Development of the model of rat isolated perfused heart for the evaluation of anthracycline cardiotoxicity and its circumvention.
Pouna P; Bonoron-Adèle S; Gouverneur G; Tariosse L; Besse P; Robert J
Br J Pharmacol; 1996 Apr; 117(7):1593-9. PubMed ID: 8730759
[TBL] [Abstract][Full Text] [Related]
4. Preclinical assessment of anthracycline cardiotoxicity in laboratory animals: predictiveness and pitfalls.
Robert J
Cell Biol Toxicol; 2007 Jan; 23(1):27-37. PubMed ID: 17041747
[TBL] [Abstract][Full Text] [Related]
5. Taxoids in combination with anthracyclines and other agents: pharmacokinetic considerations.
D'Incalci M; Schüller J; Colombo T; Zucchetti M; Riva A
Semin Oncol; 1998 Dec; 25(6 Suppl 13):16-20. PubMed ID: 9865687
[TBL] [Abstract][Full Text] [Related]
6. Paclitaxel and docetaxel stimulation of doxorubicinol formation in the human heart: implications for cardiotoxicity of doxorubicin-taxane chemotherapies.
Salvatorelli E; Menna P; Cascegna S; Liberi G; Calafiore AM; Gianni L; Minotti G
J Pharmacol Exp Ther; 2006 Jul; 318(1):424-33. PubMed ID: 16614166
[TBL] [Abstract][Full Text] [Related]
7. Paclitaxel and docetaxel enhance the metabolism of doxorubicin to toxic species in human myocardium.
Minotti G; Saponiero A; Licata S; Menna P; Calafiore AM; Teodori G; Gianni L
Clin Cancer Res; 2001 Jun; 7(6):1511-5. PubMed ID: 11410484
[TBL] [Abstract][Full Text] [Related]
8. Epirubicin in combination with the taxanes.
Trudeau M; Pagani O
Semin Oncol; 2001 Aug; 28(4 Suppl 12):41-50. PubMed ID: 11552229
[TBL] [Abstract][Full Text] [Related]
9. Cardiotoxic effects of anthracycline-taxane combinations.
Perotti A; Cresta S; Grasselli G; Capri G; Minotti G; Gianni L
Expert Opin Drug Saf; 2003 Jan; 2(1):59-71. PubMed ID: 12904125
[TBL] [Abstract][Full Text] [Related]
10. Epirubicin/taxane combinations in breast cancer: experience from several Italian trials.
Conte P; Gennari A; Guarneri V; Landucci E; Donati S; Salvadori B; Bengala C; Orlandini C; Baldini E
Oncology (Williston Park); 2001 May; 15(5 Suppl 7):21-3. PubMed ID: 11396360
[TBL] [Abstract][Full Text] [Related]
11. Evaluation of anthracycline cardiotoxicity with the model of isolated, perfused rat heart: comparison of new analogues versus doxorubicin.
Pouna P; Bonoron-Adèle S; Gouverneur G; Tariosse L; Besse P; Robert J
Cancer Chemother Pharmacol; 1995; 35(3):257-61. PubMed ID: 7805186
[TBL] [Abstract][Full Text] [Related]
12. Long-term and short-term models for studying anthracycline cardiotoxicity and protectors.
Robert J
Cardiovasc Toxicol; 2007; 7(2):135-9. PubMed ID: 17652818
[TBL] [Abstract][Full Text] [Related]
13. Effect of low-protein diet on anthracycline pharmacokinetics and cardiotoxicity.
El-Demerdash E; Ali AA; El-Taher DE; Hamada FM
J Pharm Pharmacol; 2012 Mar; 64(3):344-52. PubMed ID: 22309266
[TBL] [Abstract][Full Text] [Related]
14. Cardiotoxicity of doxorubicin/paclitaxel combination in rats: effect of sequence and timing of administration.
Saad SY; Najjar TA; Alashari M
J Biochem Mol Toxicol; 2004; 18(2):78-86. PubMed ID: 15122649
[TBL] [Abstract][Full Text] [Related]
15. Doxorubicin/taxane combinations: cardiac toxicity and pharmacokinetics.
Sparano JA
Semin Oncol; 1999 Jun; 26(3 Suppl 9):14-9. PubMed ID: 10426454
[TBL] [Abstract][Full Text] [Related]
16. In vitro modeling of the structure-activity determinants of anthracycline cardiotoxicity.
Menna P; Minotti G; Salvatorelli E
Cell Biol Toxicol; 2007 Jan; 23(1):49-62. PubMed ID: 17031515
[TBL] [Abstract][Full Text] [Related]
17. Experimental study of dexrazoxane-anthracycline combinations using the model of isolated perfused rat heart.
Plandé J; Platel D; Tariosse L; Robert J
Toxicol Lett; 2006 Feb; 161(1):37-42. PubMed ID: 16129573
[TBL] [Abstract][Full Text] [Related]
18. Pharmacokinetic profiles of doxorubicin in combination with taxanes.
Holmes FA; Rowinsky EK
Semin Oncol; 2001 Aug; 28(4 Suppl 12):8-14. PubMed ID: 11552225
[TBL] [Abstract][Full Text] [Related]
19. Pharmacokinetic characterization of amrubicin cardiac safety in an ex vivo human myocardial strip model. I. Amrubicin accumulates to a lower level than doxorubicin or epirubicin.
Salvatorelli E; Menna P; Surapaneni S; Aukerman SL; Chello M; Covino E; Sung V; Minotti G
J Pharmacol Exp Ther; 2012 May; 341(2):464-73. PubMed ID: 22338033
[TBL] [Abstract][Full Text] [Related]
20. Use of dexrazoxane as a cardioprotectant in patients receiving doxorubicin or epirubicin chemotherapy for the treatment of cancer. The Provincial Systemic Treatment Disease Site Group.
Seymour L; Bramwell V; Moran LA
Cancer Prev Control; 1999 Apr; 3(2):145-59. PubMed ID: 10474762
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
